Dr. Palkowitz is currently President and CEO at the Indiana Biosciences Research Institute, a not-for-profit translational institute focused on finding novel treatments for diabetes, pediatric rare diseases, and Alzheimer's disease. He is also Senior Research Professor of Medicine at the Indiana University School of Medicine (IUSM) in the Division of Clinical Pharmacology. He currently leads the IUSM-Purdue TREAT-AD Center, an NIH-NIA funded initiative focused on discovering potential new therapies for Alzheimer’s disease. He is also co-founder of Monument Biosciences, a biotech company focusing on discovery and development of next generation treatments for Alzheimer's disease and related dementias. Prior to his current roles, Dr. Palkowitz served as the vice president of Discovery Chemistry Research and Technologies at Eli Lilly and Company, where he worked for 28 years. In his role as vice president, Dr. Palkowitz was responsible for the global small molecule drug discovery strategy and delivery of clinical candidates in disease areas including cancer, diabetes, immunology, pain and neurodegenerative disorders. As a member of the Lilly Research Laboratories leadership team, Dr. Palkowitz participated in setting strategic direction for the company along with governance of the discovery and early clinical development pipeline.Additionally, Dr. Palkowitz has served on several prominent advisory committees including most recently the NIH NCATS Advisory Council and the National Academy of Sciences Board on Chemical Sciences and Technologies. He has published numerous research articles and is an inventor on almost 60 US patents. Dr. Palkowitz obtained his PhD in synthetic organic chemistry from the Massachusetts Institute of Technology and his bachelor’s degree in chemistry from the University of California at Berkeley.